Tracking children's immune responses reveals an antibody blueprint for fighting malaria

What is it about?

Malaria caused by Plasmodium vivax is a major global health problem, affecting millions of people worldwide — yet efforts to reduce its impact have slowed, and no effective vaccine currently exists. One key reason for this is that we still don't fully understand how the human immune system successfully fights off this parasite. To address this, we developed a new tools to study how antibodies fight infection by P. vivax. Crucially, we assessed how antibodies recruit and activate other immune components to provide protective immunity. The study followed a group of children living in a malaria-endemic areas over time enabling real-world insights into how immunity develops. The study identified specific proteins on the surface of P. vivax that are recognised and targeted by antibodies with protective functions. We evaluated thousands of different combinations of antibodies to find out which groupings were most strongly linked to protection against malaria.

Featured Image

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Why is it important?

These findings open multiple new avenues for vaccine development to overcome existing roadblocks, particularly developing vaccines that can generate potent antibodies for maximal protective immunity. A highly protective vaccine will greatly facilitate achieving and sustaining malaria elimination in the future.